stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) EBITDA
Fortrea Holdings Inc.'s EBITDA for fiscal 2025 was $3.3M, compared with −$51.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $91.5M. Over the past ten years it has ranged from −$51.0M (fiscal 2024) to $290.5M (fiscal 2022); the current reading is higher than 33% of that period. Fortrea Holdings Inc. ranks 27th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.3M | — |
| FY2024 | −$51.0M | — |
| FY2023 | $143.4M | (50.64%) |
| FY2022 | $290.5M | 3.53% |
| FY2021 | $280.6M | 8.34% |
| FY2020 | $259.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $35.0M | 1.74% |
| Jun 2026 | $34.4M | 109.76% |
| Mar 2026 | $16.4M | 187.73% |
| Dec 2025 | $5.7M | (48.18%) |
| 13 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $243.7M |
| FTRE Fortrea Holdings Inc. | $91.5M |
| SRPT Sarepta Therapeutics, Inc. compare | −$101.5M |
| ZYME Zymeworks Inc. compare | −$146.1M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. compare | −$198.6M |
| REPL Replimune Group, Inc. compare | −$266.7M |
| IMNM Immunome, Inc. compare | −$268.3M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item